TD Cowen initiated coverage of Senseonics (SENS) with a Buy rating and $1.25 price target The firm says the company is positioned for accelerated growth following the U.S. launch of Eversense 365, its year-long implantable continuous glaucous monitoring device. Senseonics is gaining market share and its pipeline should further enhance its competitiveness, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SENS:
- Strong Growth Potential and Strategic Initiatives Drive Buy Rating for Senseonics Holdings
- Senseonics price target raised to $1.40 from $1.10 at H.C. Wainwright
- Nucor, Charter, Senseonics, Shake Shack, Altimmune: Trending by Analysts
- Senseonics assumed with a Buy at H.C. Wainwright
- Senseonics Holdings Approves Director Elections and Proposals